Key clinical point: Real-world analysis demonstrated a higher efficacy of non-tumor necrosis factor inhibitors (non-TNFi) vs TNFi and Janus kinase inhibitors (JAKi) vs biologic disease-modifying antirheumatic drugs (bDMARD) in patients with rheumatoid arthritis (RA), along with a higher efficacy of adalimumab, etanercept, and golimumab vs infliximab within TNFi.
Major finding: Efficacies of TNFi vs non-TNFi drugs (risk ratio [RR] 0.88; P < .01) and bDMARD vs JAKi (RR 0.86; P < .01) were lower. Among TNFi, adalimumab, etanercept, and golimumab were 19.0% more effective than infliximab (RR 1.19; P < .01).
Study details: This was a systematic review and meta-analysis of 21 population-based, prospective, and retrospective cohort studies including 182,098 patients with RA.
Disclosures: This study was supported by the Secretariat of Science, Technology, Innovation, and Strategic Inputs of the Ministry of Health, Brazil, and the Oswaldo Cruz Foundation, Fiocruz. The authors declared no conflicts of interest.
Source: de Castro CT et al. Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis. Front Pharmacol. 2022;13:927179 (Aug 11). Doi: 10.3389/fphar.2022.927179